EVNIN LUKE 4
4 · Werewolf Therapeutics, Inc. · Filed May 29, 2026
Research Summary
AI-generated summary of this filing
Werewolf Therapeutics (HOWL) Director Luke Evnin Sells Shares
What Happened
- Luke Evnin, a director (and manager of related MPM entities), sold a total of 141,106 Werewolf Therapeutics (HOWL) shares in three open‑market disposals from May 27–29, 2026 under a Rule 10b5‑1 plan. The sales were:
- 05/27/2026: 80,852 shares at a weighted avg price $0.48 — proceeds ~$38,809 (sales executed across affiliated funds).
- 05/28/2026: 27,698 shares at a weighted avg price $0.46 — proceeds ~$12,741.
- 05/29/2026: 32,556 shares at a weighted avg price $0.45 — proceeds ~$14,650.
- Total proceeds across the three transactions were roughly $66,200. These were sales (disposals), which are often routine; the transactions were effected pursuant to a 10b5‑1 trading plan (see footnote).
Key Details
- Transaction dates & price ranges:
- 05/27/2026: weighted avg $0.48 (individual trades ranged $0.455–$0.4858).
- 05/28/2026: weighted avg $0.46 (individual trades ranged $0.46–$0.49705).
- 05/29/2026: weighted avg $0.45 (individual trades ranged $0.44–$0.4557).
- Shares owned after the final sale (05/29/2026): 622,579 shares held across related entities (66,701 by AM LLC; 421,155 by MPM BioVentures 2014; 28,088 by BV2014(B); 14,493 by AM BV2014; 92,142 by MPM Oncology Innovations Fund).
- Sales were executed by affiliated funds as broken out per trade (e.g., AM LLC, BV 2014, BV 2014(B), AM BV2014, MPM OIF).
- Notable footnotes: Transactions effected pursuant to a Rule 10b5‑1 plan dated March 26, 2026; reporting person (Luke Evnin) is a member/manager of the listed entities and disclaims direct beneficial ownership except to the extent of pecuniary interest.
- Filing timeliness: Form 4 filed 2026‑05‑29 covering trades 05/27–05/29 — reported within the usual Form 4 reporting window.
Context
- These were straight sales by funds affiliated with Evnin (institutional/managed‑fund disposals), not option exercises or gifts. Sales under a 10b5‑1 plan are pre‑arranged and are commonly executed for liquidity or portfolio management rather than signaling new company views.
Insider Transaction Report
Form 4
EVNIN LUKE
Director
Transactions
- Sale
Common Stock
[F1][F2][F3][F4][F5]2026-05-27$0.48/sh−80,852$38,809→ 682,833 total(indirect: See Footnotes) - Sale
Common Stock
[F1][F6][F7][F4][F8]2026-05-28$0.46/sh−27,698$12,741→ 655,135 total(indirect: See Footnotes) - Sale
Common Stock
[F1][F9][F10][F4][F11]2026-05-29$0.45/sh−32,556$14,650→ 622,579 total(indirect: See Footnotes)
Footnotes (11)
- [F1]Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.44 to $0.4557 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F11]The shares are held as follows: 66,701 by AM LLC, 421,155 by BV 2014, 28,088 by BV 2014(B), 14,493 by AM BV2014 and 92,142 by MPM OIF.
- [F2]The shares were sold as follows: 8,663 by MPM Asset Management LLC ("AM LLC"), 54,692 by MPM BioVentures 2014, L.P. ("BV 2014"), 3,648 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 1,883 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 11,966 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.46 to $0.49705 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- [F5]The shares are held as follows: 73,157 by AM LLC, 461,914 by BV 2014, 30,807 by BV 2014(B), 15,896 by AM BV2014 and 101,059 by MPM OIF.
- [F6]The shares were sold as follows: 2,968 by AM LLC, 18,736 by BV 2014, 1,250 by BV 2014(B), 645 by AM BV2014 and 4,099 by MPM OIF.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.455 to $0.4858 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The shares are held as follows: 70,189 by AM LLC, 443,178 by BV 2014, 29,557 by BV 2014(B), 15,251 by AM BV2014 and 96,960 by MPM OIF.
- [F9]The shares were sold as follows: 3,488 by AM LLC, 22,023 by BV 2014, 1,469 by BV 2014(B), 758 by AM BV2014 and 4,818 by MPM OIF.
Signature
/s/ Luke Evnin|2026-05-29